Different Involvement of Promoter Methylation in the Expression of Organic Cation/carnitine Transporter 2 (OCTN2) in Cancer Cell Lines

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Oct 23

PMID 24146874

Citations 11

Authors

Qiang Qu

Jian Qu

Min Zhan

Lan-Xiang Wu

Yi-Wen Zhang

Xiao-Ya Lou

Li-Juan Fu

Hong-Hao Zhou

Affiliations

Soon will be listed here.

Abstract

Organic cation/carnitine transporter 2 (OCTN2) is responsible for the cellular uptake of the antineoplastic agent, oxaliplatin. Epigenetic modification is a possible mechanism of altered drug-transporter expression in cancers, leading to altered efficacy of chemotherapeutic drugs. However, the mechanisms governing OCTN2 regulation are not completely understood. In this study, the low levels of OCTN2 in HepG2 and LS174T cells were elevated by the demethylating reagent, decitabine (DCA). To further reveal the epigenetic mechanism of down-regulation of OCTN2, we found that Region-1 within the OCTN2 promoter (spanning -354 to +85) was a determinant of OCTN2 expression in a luciferase reporter assay. Moreover, methylation-specific PCR (MSP) and bisulfite genomic sequencing showed that the degree of individual methylated CpG sites within this region was inversely correlated with the levels of OCTN2 in different cancer cells. Application of DCA to HepG2 and LS174T cells reversed the hypermethylation status of the OCTN2 promoter and increased OCTN2 expression, enhancing cellular uptake of oxaliplatin. Thus, we identified that promoter methylation is responsible for epigenetic down-regulation of OCTN2 in HepG2 and LS174T cells. Given the essential role of OCTN2 in cancer cell uptake of chemotherapeutics, and thus treatment efficacy, pretreatment with a demethylating reagent is a possible strategy for optimizing pharmacotherapies against cancers.

Citing Articles

Dysfunction of the carnitine cycle in tumor progression.

Wang X, Yang C, Huang C, Wang W Heliyon. 2024; 10(16):e35961.

PMID: 39211923 PMC: 11357771. DOI: 10.1016/j.heliyon.2024.e35961.

The Human OCTN Sub-Family: Gene and Protein Structure, Expression, and Regulation.

Galluccio M, Tripicchio M, Pochini L Int J Mol Sci. 2024; 25(16).

PMID: 39201429 PMC: 11354717. DOI: 10.3390/ijms25168743.

Inflammation and Organic Cation Transporters Novel (OCTNs).

Pochini L, Galluccio M, Console L, Scalise M, Eberini I, Indiveri C Biomolecules. 2024; 14(4).

PMID: 38672410 PMC: 11048549. DOI: 10.3390/biom14040392.

Clinical Significance of Carnitine in the Treatment of Cancer: From Traffic to the Regulation.

Farahzadi R, Hejazi M, Molavi O, Pishgahzadeh E, Montazersaheb S, Jafari S Oxid Med Cell Longev. 2023; 2023:9328344.

PMID: 37600065 PMC: 10435298. DOI: 10.1155/2023/9328344.

Zhou S, Shu Y Drug Metab Dispos. 2022; 50(9).

PMID: 35644529 PMC: 9488976. DOI: 10.1124/dmd.121.000704.

References

Yoon Y, Lee D, Ki C, Lee S, Kim J, Lee Y . SLC22A5 mutations in a patient with systemic primary carnitine deficiency: the first Korean case confirmed by biochemical and molecular investigation. Ann Clin Lab Sci. 2012; 42(4):424-8. View

Aoki M, Terada T, Kajiwara M, Ogasawara K, Ikai I, Ogawa O . Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation. Am J Physiol Renal Physiol. 2008; 295(1):F165-70. DOI: 10.1152/ajprenal.90257.2008. View

Yamazaki K, Takazoe M, Tanaka T, Ichimori T, Saito S, Iida A . Association analysis of SLC22A4, SLC22A5 and DLG5 in Japanese patients with Crohn disease. J Hum Genet. 2004; 49(12):664-668. DOI: 10.1007/s10038-004-0204-x. View

Herman J, Graff J, Myohanen S, Nelkin B, Baylin S . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821-6. PMC: 38513. DOI: 10.1073/pnas.93.18.9821. View

Chu S, Feng D, Ma Y, Zhang H, Zhu Z, Li Z . Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. J Transl Med. 2011; 9:156. PMC: 3184631. DOI: 10.1186/1479-5876-9-156. View

Moffatt M, Gut I, Demenais F, Strachan D, Bouzigon E, Heath S . A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010; 363(13):1211-1221. PMC: 4260321. DOI: 10.1056/NEJMoa0906312. View

Sheikhnejad G, Brank A, Christman J, Goddard A, Alvarez E, Ford Jr H . Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine. J Mol Biol. 1999; 285(5):2021-34. DOI: 10.1006/jmbi.1998.2426. View

Brim H, Kumar K, Nazarian J, Hathout Y, Jafarian A, Lee E . SLC5A8 gene, a transporter of butyrate: a gut flora metabolite, is frequently methylated in African American colon adenomas. PLoS One. 2011; 6(6):e20216. PMC: 3110579. DOI: 10.1371/journal.pone.0020216. View

Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, SHIMANE M . Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem. 1998; 273(32):20378-82. DOI: 10.1074/jbc.273.32.20378. View

10.

Herman J, Baylin S . Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349(21):2042-54. DOI: 10.1056/NEJMra023075. View

11.

Siedlecki P, Garcia Boy R, Musch T, Brueckner B, Suhai S, Lyko F . Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem. 2006; 49(2):678-83. DOI: 10.1021/jm050844z. View

12.

Fisher S, Hampe J, Onnie C, Daly M, Curley C, Purcell S . Direct or indirect association in a complex disease: the role of SLC22A4 and SLC22A5 functional variants in Crohn disease. Hum Mutat. 2006; 27(8):778-85. DOI: 10.1002/humu.20358. View

13.

Koch A, Konig B, Stangl G, Eder K . PPAR alpha mediates transcriptional upregulation of novel organic cation transporters-2 and -3 and enzymes involved in hepatic carnitine synthesis. Exp Biol Med (Maywood). 2008; 233(3):356-65. DOI: 10.3181/0706-RM-168. View

14.

Wu X, Prasad P, Leibach F, Ganapathy V . cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun. 1998; 246(3):589-95. DOI: 10.1006/bbrc.1998.8669. View

15.

Angelini S, Pantaleo M, Ravegnini G, Zenesini C, Cavrini G, Nannini M . Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol Res. 2012; 68(1):1-6. DOI: 10.1016/j.phrs.2012.10.015. View

16.

Boyes J, Bird A . DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell. 1991; 64(6):1123-34. DOI: 10.1016/0092-8674(91)90267-3. View

17.

Martin V, Sanchez-Sanchez A, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega M . Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer. 2013; 108(10):2005-12. PMC: 3670480. DOI: 10.1038/bjc.2013.188. View

18.

Kurimoto M, Matsuoka H, Hanaoka N, Uneda S, Murayama T, Sonoki T . Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. Leukemia. 2012; 27(1):233-5. PMC: 3542629. DOI: 10.1038/leu.2012.178. View

19.

DArgenio G, Petillo O, Margarucci S, Torpedine A, Calarco A, Koverech A . Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis. J Biol Chem. 2010; 285(35):27078-27087. PMC: 2930707. DOI: 10.1074/jbc.M110.109678. View

20.

Shoji Y, Koizumi A, Kayo T, Ohata T, Takahashi T, Harada K . Evidence for linkage of human primary systemic carnitine deficiency with D5S436: a novel gene locus on chromosome 5q. Am J Hum Genet. 1998; 63(1):101-8. PMC: 1377235. DOI: 10.1086/301911. View